Redeye makes negligible estimate revisions on the back of Climeon’s Q2 figures which was in line with our estimates. The absence of new orders has increased the pressure, but the company seems increasingly optimistic to sign new deals in the near term. The outcome of the share warrant program was below our expectations, resulting in a lowered fair value range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/